Capture réglementaire en temps de pandémie
In the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. This gave the company seven years of market exclusivity for its drug in the US market....
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association Recherche & Régulation
2021-02-01
|
| Series: | Revue de la Régulation |
| Subjects: | |
| Online Access: | https://journals.openedition.org/regulation/17621 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832577968909582336 |
|---|---|
| author | Samira Guennif |
| author_facet | Samira Guennif |
| author_sort | Samira Guennif |
| collection | DOAJ |
| description | In the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. This gave the company seven years of market exclusivity for its drug in the US market. This decision was immediately denounced as a clear misuse of the Orphan Drug Act (ODA) administered by the FDA under the influence of the pharmaceutical industry; a case of regulatory capture. The purpose of this article is to explore the concept of regulatory capture, drawing on work developed in the field of political science and (international) political economy, and based on the case study of remdesivir. It is shown that there have been multiple captures around a public good: agency, statutory, corrosive or cultural captures, to draw on the work of Carpenter (2014) developed in a break with those of economic regulation theory. Finally, recommendations are made to strengthen the ODA and limit its vulnerability to capture. |
| format | Article |
| id | doaj-art-7d86779126ee44e5aa9b2a73edb85817 |
| institution | Kabale University |
| issn | 1957-7796 |
| language | English |
| publishDate | 2021-02-01 |
| publisher | Association Recherche & Régulation |
| record_format | Article |
| series | Revue de la Régulation |
| spelling | doaj-art-7d86779126ee44e5aa9b2a73edb858172025-01-30T14:25:57ZengAssociation Recherche & RégulationRevue de la Régulation1957-77962021-02-012910.4000/regulation.17621Capture réglementaire en temps de pandémieSamira GuennifIn the midst of the covid-19 pandemic, the Food and Drug Administration (FDA) published in March the orphan drug status granted to remdesivir, a molecule patented by Gilead as a treatment for the new coronavirus. This gave the company seven years of market exclusivity for its drug in the US market. This decision was immediately denounced as a clear misuse of the Orphan Drug Act (ODA) administered by the FDA under the influence of the pharmaceutical industry; a case of regulatory capture. The purpose of this article is to explore the concept of regulatory capture, drawing on work developed in the field of political science and (international) political economy, and based on the case study of remdesivir. It is shown that there have been multiple captures around a public good: agency, statutory, corrosive or cultural captures, to draw on the work of Carpenter (2014) developed in a break with those of economic regulation theory. Finally, recommendations are made to strengthen the ODA and limit its vulnerability to capture.https://journals.openedition.org/regulation/17621pharmaceutical industrypublic healthpandemicmedicineregulatory capture |
| spellingShingle | Samira Guennif Capture réglementaire en temps de pandémie Revue de la Régulation pharmaceutical industry public health pandemic medicine regulatory capture |
| title | Capture réglementaire en temps de pandémie |
| title_full | Capture réglementaire en temps de pandémie |
| title_fullStr | Capture réglementaire en temps de pandémie |
| title_full_unstemmed | Capture réglementaire en temps de pandémie |
| title_short | Capture réglementaire en temps de pandémie |
| title_sort | capture reglementaire en temps de pandemie |
| topic | pharmaceutical industry public health pandemic medicine regulatory capture |
| url | https://journals.openedition.org/regulation/17621 |
| work_keys_str_mv | AT samiraguennif capturereglementaireentempsdepandemie |